Last reviewed · How we verify
Vehicle to bimatoprost solution
Vehicle to bimatoprost solution is a Prostaglandin F analog Small molecule drug developed by Allergan. It is currently in Phase 3 development for Open-angle glaucoma, Ocular hypertension.
Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Vehicle to bimatoprost solution |
|---|---|
| Sponsor | Allergan |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Bimatoprost binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, enhancing drainage of aqueous humor through the uveoscleral (unconventional) pathway. This mechanism reduces intraocular pressure, which is the primary pathogenic factor in glaucoma and ocular hypertension. The vehicle formulation optimizes drug delivery and stability for topical ophthalmic administration.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Foreign body sensation
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis (PHASE3)
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis (PHASE3)
- Bimatoprost for the Treatment of Eyebrow Hypotrichosis (PHASE3)
- Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children (PHASE4)
- SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) (PHASE4)
- Bimatoprost in the Treatment of Eyelash Hypotrichosis (PHASE3)
- Topical Bimatoprost Effect on Androgen Dependent Hair Follicles (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle to bimatoprost solution CI brief — competitive landscape report
- Vehicle to bimatoprost solution updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about Vehicle to bimatoprost solution
What is Vehicle to bimatoprost solution?
How does Vehicle to bimatoprost solution work?
What is Vehicle to bimatoprost solution used for?
Who makes Vehicle to bimatoprost solution?
What drug class is Vehicle to bimatoprost solution in?
What development phase is Vehicle to bimatoprost solution in?
What are the side effects of Vehicle to bimatoprost solution?
What does Vehicle to bimatoprost solution target?
Related
- Drug class: All Prostaglandin F analog drugs
- Target: All drugs targeting Prostaglandin F receptor (FP receptor)
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Compare: Vehicle to bimatoprost solution vs similar drugs
- Pricing: Vehicle to bimatoprost solution cost, discount & access